Acurx Pharmaceuticals (ACXP) Return on Capital Employed (2025 - 2026)
Acurx Pharmaceuticals' (ACXP) quarterly Return on Capital Employed came in at 125.35% in Q1 2026, up 52327.0% YoY from N/an in Q1 2025, and up 30.65% on a QoQ basis from 180.77% in Q4 2025.
Acurx Pharmaceuticals (ACXP) Return on Capital Employed (2025 - 2026) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 2 years of Return on Capital Employed data on file, last reported at 125.35% in Q1 2026.
- Quarterly Return on Capital Employed rose 52327.0% year-over-year to 125.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 125.35% (up 52327.0% YoY) and the FY2025 annual result came in at 241.35%, up 31453.0% from the prior year.
- Return on Capital Employed improved to 125.35% in Q1 2026, from 180.77% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 125.35% in Q1 2026 to a low of 648.63% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 7.88% |
| 10 | Acurx Pharmaceuticals | 6.37 Mn | 6.37 Mn | - | -103.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -103.22% |
| Mar 31, 2026 | -125.35% |
| Dec 31, 2025 | -180.77% |
| Sep 30, 2025 | -253.01% |
| Jun 30, 2025 | -348.31% |
| Mar 31, 2025 | -648.63% |